11 research outputs found
High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
Get PDF
Management and outcome of venous thromboembolic events (VTEs) during sunitinib treatment
No full textCoexpression of EGFR, pEGFR, VEGF, pVEGF, PTEN, pAKT, and p21 in colorectal cancer patients can have IHC variability between metastases and primary tumours and for EGFR-targeted therapies, p21 and VEGF appear reliably as predictive factors of response
No full textFrequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis as a surrogate marker for disease management
No full textTopoisomerase II-alpha (Top2A) and chromosome 17 abnormalities in locally advanced soft tissue sarcomas (LASTS)
No full textDoes interruption of imatinib (IM) in responding GIST patients after one year of treatment influence the secondary resistance to IM after its reintroduction? Updated results of the prospective French Sarcoma Group randomized phase III trial on long term survival
No full textp53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes
No full textPhase I trial of intravenous Ad5CRT in patients with liver metastasis of gastrointestinal cancers
No full textSMAD4 and TS expression might predict the risk of recurrence after resection of colorectal liver metastases
No full text
